BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fournier L, de Geus-Oei LF, Regge D, Oprea-Lager DE, D'Anastasi M, Bidaut L, Bäuerle T, Lopci E, Cappello G, Lecouvet F, Mayerhoefer M, Kunz WG, Verhoeff JJC, Caruso D, Smits M, Hoffmann RT, Gourtsoyianni S, Beets-Tan R, Neri E, deSouza NM, Deroose CM, Caramella C. Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper. Front Oncol 2021;11:800547. [PMID: 35083155 DOI: 10.3389/fonc.2021.800547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Iannessi A, Beaumont H. Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us? Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.988784] [Reference Citation Analysis]
2 Belkouchi Y, Nebot-bral L, Lawrance L, Kind M, David C, Ammari S, Cournède P, Talbot H, Vuagnat P, Smolenschi C, Kannouche PL, Chaput N, Lassau N, Hollebecque A. Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.982790] [Reference Citation Analysis]